Basic Information
-
Targeting strategy
-
Gene targeting strategy for B-hIL33 mice. The exons 2-8 of mouse Il33 gene that encode the full-length protein was replaced by human IL33 exons 2-8 in B-hIL33 mice.
-
Protein expression analysis
-
Lung abrasive fluid from both wild type (WT) C57BL/6 and homozygous B-hIL33 mice were analyzed by ELISA. When treated with LPS, mouse IL33 was detectable in the WT mice, while human IL33 was detectable in the homozygous B-hIL33 mice, albeit being at a lower level. ND, not detectable. n=3.
-
Model schematic and antibody evaluation scheme
-
-
Immune cell profile
-
The proportion of BALF immune cells in acute mouse asthma model
BALF immune cell profiles in acute mouse asthma model. BALF Immune cells were isolated from B-hIL33 mice (n=5). The number of CD45+ cells and eosinophils were determined by flow cytometry in acute asthma mice treated with or without Etokimab analog. Treatment of Etokimab analog can reduce the inflammatory cells in homozygous B-hIL33 mice as opposed to in untreated mice.
The number of BALF immune cells in acute mouse asthma model
BALF immune cell profiles in acute mouse asthma model. BALF Immune cells were isolated from B-hIL33 mice (n=5). The number of eosinophils were determined by flow cytometry in acute asthma mice treated with or without Etokimab analog. Treatment of Etokimab analog can reduce the inflammatory cells in homozygous B-hIL33 mice as opposed to in untreated mice.
IgE production in mouse asthma model
IgE production. Serum was collected at the study endpoint. IgE levels responded to OVA-specific antibody were analyzed. The results show that the levels of IgE in mice treated with Etokimab is much lower than that in untreated mice.
-
H&E stain in mouse asthma model
-
Airways from B-hIL33 mice exposed to PBS aerosols did not show any inflammation. OVA exposure resulted in a significant increase in peribronchial and perivascular inflammatory infiltrates, as well as increase in the level of mucus secretion. A reduction in inflammatory infiltrates and mucus secretion was observed in mice treated with Etokimab analog.
